Ingenuity Systems has announced that the Genomics Institute of the Novartis Research Foundation (GNF) has entered into an agreement to renew and expand the number of licenses to the Ingenuity Pathway Analysis (IPA) software for use in their research programs.
GNF says that it has used IPA since 2003 and has cited it in published research. John Walker, Group Leader of RNA Profiling at GNF, co-authored a paper published in Chemistry and Biology titled “Purmorphamine induces osteogenesis by activation of the hedgehog-signaling pathway,” which describes the use of IPA to determine the mechanism of action of a biologically-active small molecule, which is a sometimes daunting task.
Ingenuity Pathways Analysis is a software application that can enable researchers to model, analyze and understand the complex biological systems at the core of life science research.
According to Ingenuity, its Pathways Analysis software is deployed in all major pharmaceutical companies and hundreds of biotechnology companies and academic institutions globally.
IPA can support analysis of all high throughput analysis platforms and is used in areas of development from target identification and validation to biomarkers, predictive toxicology, and pharmacogenomics.